MHRA launches rare disease therapy consultation in UK

On 21 May 2026, the Medicines and Healthcare products Regulatory Agency, or MHRA, opened a public consultation on a new Rare Disease Therapies Framework, with responses due by 11.59pm on 30 July 2026. This is not the launch of a new treatment. It is a consultation on new rules that could change how some very rare therapies are tested, reviewed and, in some cases, reach patients sooner. (gov.uk) That matters because rare diseases are not rare when you add them together. The consultation page says more than 3.5 million people in the UK live with a rare disease, yet only a small proportion have an approved medicinal treatment. For many families, the obstacle is not only the science. It is also that the usual approval system was built for bigger patient groups and more standard clinical trials. (gov.uk)

The MHRA says the framework is meant for therapies aimed at diseases affecting roughly one in 50,000 people or fewer in the UK, where the usual development route is clearly struggling. In plain English, it is for situations where there may be too few patients, too little background data, or too much variation between cases to run the sort of large studies regulators normally expect. (gov.uk) According to the MHRA, traditional rare disease programmes can take 10 to 12 years to reach marketing authorisation. That timeline is one reason campaigners, clinicians and patient groups have argued for years that rare disease regulation cannot just be a smaller version of mainstream drug regulation. **What this means:** the consultation is really asking whether the UK should judge evidence differently when the disease itself makes standard evidence hard to collect. (gov.uk)

The biggest idea in the draft is a new Investigational Marketing Authorisation, or IMA. The MHRA describes it as a single authorisation that would combine permission to run clinical trials with a progressive route towards full marketing authorisation, instead of making developers move through two separate approval stages. (gov.uk) If that sounds technical, think of it this way: rather than stopping one process and starting another, a developer could stay on one supervised path while more evidence comes in. The draft says this could allow rolling data submissions, modular assessment and controlled earlier access where the evidence is limited but convincing, with further safety, quality and efficacy evidence gathered after authorisation. (gov.uk)

The draft also accepts that rare disease studies may need different tools. The MHRA says it is open to adaptive trial designs, real-world evidence, patient-relevant or surrogate endpoints, predictive modelling, digital twins and some non-animal methods where these are scientifically justified. That is a long list, but the basic point is simple: when only a tiny number of people have a condition, regulators may need more flexible ways to judge whether a treatment is promising and safe enough to keep moving forward. (gov.uk) Just as important, the consultation puts patient communication near the centre of the plan. The consultation document says informed consent should be an ongoing process rather than a one-off signature, and it asks for views on how patients, carers and families should be supported when decisions are being made under uncertainty. That matters in rare disease care, where families are often weighing hope against limited evidence. (gov.uk)

This is one reason the MHRA is not asking only drug companies to respond. The consultation invites feedback from manufacturers, biotech firms, clinicians, researchers, patient organisations, carers, families and other stakeholders. In the press release, the MHRA also says industry input will help shape details such as who qualifies for IMA designation, how real-world evidence should be used, and how the new route should fit with existing schemes such as orphan designation and the Innovative Licensing and Access Pathway. (gov.uk) The draft has not appeared out of nowhere. It was developed with support from the Rare Disease Consortium, which brings together the MHRA, the Health Research Authority, NICE, the Department of Health and Social Care, NHS England, patient groups, academics and industry partners. **Why that matters:** if the regulator, the NHS and the body that judges value for money are not broadly aligned, a faster licence on paper does not automatically become faster access in real life. (gov.uk)

The government and the MHRA are also making a bigger argument about the UK’s place in life sciences. Their case is that the UK already has assets other countries want: a strong research base, a single national genomics provider, and large NHS datasets that can help with follow-up evidence after a medicine first reaches patients. (gov.uk) The proposed framework is deliberately broad. The MHRA says it is technology-agnostic, meaning it is not written for just one type of treatment. It could apply to advanced therapy medicinal products, personalised and gene-based treatments, digital-enabled medicinal products, new manufacturing approaches and even repurposed medicines. For readers outside the sector, that is a sign that the regulator expects rare disease science to come from many directions, not one model alone. (gov.uk)

Supporters of the plan are already framing it as a chance to close the gap between fast-moving science and slow-moving systems. Public Health Minister Sharon Hodgson said families living with rare disease often face long, exhausting searches for effective treatment, while MHRA executive Julian Beach said the new route is meant to streamline regulation without dropping safety standards. NICE’s Helen Knight added that the proposal could fit with NICE’s existing approach of allowing promising medicines to reach NHS patients while extra evidence is gathered. (gov.uk) Still, it is worth keeping one foot on the ground. This is a consultation, not a final law, and the draft does not promise a shortcut around proof. The MHRA says safety, quality and efficacy standards would remain in place, with stronger post-authorisation evidence gathering built into the model. In other words, the proposal is not approve first and ask questions later; it is closer to asking the right questions earlier, then keeping the checks in place as more evidence arrives. (gov.uk)

For patients and families, the most useful way to read this news is as a test of whether regulation can catch up with rare disease reality. When conditions are ultra-rare, waiting for textbook-sized datasets can mean waiting forever. The MHRA is asking whether the UK should accept smarter, more tailored evidence pathways so promising therapies are not blocked simply because the patient group is small. (gov.uk) The next step is straightforward: the consultation stays open until 11.59pm on 30 July 2026, and the MHRA says it will hold general sessions over the summer while responses are considered. If the final framework keeps patient safety clear and makes the approval path more workable, this could become one of the most important rare disease policy changes in the UK for years. (gov.uk)